IDEXX Laboratories heads into its third-quarter report with a puzzle that has frustrated shareholders for a while now. Pet owners keep visiting the vet less often, yet the company keeps raising its outlook. Management lifted nearly every major 2026 target last quarter while warning that U.S. clinical visits would remain under pressure. The stock has dropped about 7% since that report while the S&P 500 was essentially flat. The November 2 release, due before the open, is a test of whether pricing power and new diagnostics can keep doing the heavy lifting when foot traffic will not.
The Street is looking for earnings of $3.71 a share on revenue of about $1.19 billion. That would mean EPS growth of roughly 9% and revenue growth near 8% from a year ago, when IDEXX earned $3.40 on $1.11 billion. That is solid compounding, not acceleration. A step down from the second quarter's $4.27 and $1.22 billion is normal seasonality, and it also reflects management's plan to spend more on sales and R&D in the back half. The whisper number of $3.82 sits about 3% above consensus. That suggests the people closest to the stock expect another beat and not just a match.
Guidance frames that bar. Management now sees full-year EPS of $14.69 to $14.94, up from $14.45 to $14.90. Consensus of $14.68 sits a hair below even the low end of that range. Revenue consensus of $4.72 billion lands near the middle of the $4.70 billion to $4.745 billion outlook, which already absorbs a $15 million currency headwind. In other words, analysts have not fully bought the raised profit view. A clean quarter could force estimates up, while a stumble would confirm the skepticism.
The operating story rests on recurring diagnostics, where management raised its organic growth target to 9.5% to 10.7%. That is a bold call when U.S. same-store visits fell 1.3% last quarter, wellness visits slid 3.4%, and the company is planning for roughly a 1.5% visit decline in the second half. Bridging that gap requires more testing per visit, and the newly broadened menu is the evidence to watch. CancerDx has passed 10,000 ordering clinics and expanded into a panel in late Q3 that adds mast cell tumor detection at no extra charge. InViewDX fine needle aspirate testing broadened during the quarter on its way to wide availability by year-end. SDMA is now built into chemistry profiles for all North American customers. Signs that these tools are lifting volume would validate the thesis. Recurring growth slipping toward the bottom of the range would challenge it.
Instruments are a second swing factor. Instrument revenue fell 20% organically last quarter as IDEXX lapped the prior-year InView launch. Investors should want to see that drag ease, alongside continued strength in DR50+ digital radiography after six straight record quarters of placements. Placements feed future consumable revenue, so they matter more than their immediate sales suggest. Margins deserve attention too. The 70 to 90 basis point improvement target leaves little cushion if second-half investments run hot.
Sentiment has warmed noticeably, improving from strongly bearish before last quarter to only slightly negative now, even as the stock has fallen. Shares trade near $560, below the 200-day average of about $577 and roughly midway between the post-earnings low of $500.61 and high of $624.15. That leaves room to move either way. The central question is simple. If innovation-driven testing keeps recurring diagnostics near 10% growth despite fewer visits, the raised outlook looks credible and the discount looks overdone. If it does not, the visit problem becomes the whole story.